Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a narrative review article synthesizing preclinical and early translational work on carrier-free nanoparticles; it raises questions and organizes the field rather than reporting original clinical trial data or definitive evidence.
A narrative review synthesizing preliminary open-label clinical evidence and putative mechanisms without new empirical data; the source itself acknowledges small sample sizes, lack of controlled trials, and unresolved safety and dosing questions, positioning propofol as a candidate for future study rather than an established therapeutic.